Pihlajalinna Oyj (PIHLIS) Fair Value & Analysis
Healthcare · FI · Market cap €234M
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 24 days ago
Fair value updated Jul 17, 2026, revised from €32.69 to €31.56 (−3.5%) since Jun 25, 2026. Share price +0.2% over the past month.
A solid business, screening 200% undervalued on our models.
What matters now
- The price is below even our cautious bear case (€20.76). The market is more pessimistic than our downside scenario.
- Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (€20.76 to €42.36) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range €6.30 – €16.30 · fair‑value band €20.76 – €42.36 · the €10.52 price screens below the €31.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Pihlajalinna Oyj (PIHLIS) currently trades at €10.52, while our model-based Fair Value estimate is €31.56, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Pihlajalinna Oyj generated revenue of €613M at a net margin of 5.7%. Revenue declined 21.7% year over year. It earns a return on equity of 20.7%. Net debt stands at €271M. Fundamentals as of Jul 17, 2026
Our scenario range runs from €20.76 (bear case) to €42.36 (bull case); at €10.52, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 200%, PIHLIS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (€35.14) versus Dividend Discount (€4.87). Highest evidence: Growth DCF (80).
Notify me when PIHLIS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pihlajalinna Oyj provides social, healthcare, and wellbeing services to private persons, companies, insurance companies, and public sector entities in Finland. It operates in two segments, Private Healthcare Services and Public Services.
Full company description
Pihlajalinna Oyj provides social, healthcare, and wellbeing services to private persons, companies, insurance companies, and public sector entities in Finland. It operates in two segments, Private Healthcare Services and Public Services. The company offers general practitioner and medical specialist, occupational healthcare, social and healthcare outsourcing, fitness center, responsible doctor, and remote consultation services, as well as residential and staffing services. It also provides occupational health services to private clinics and hospitals, responsible doctor, diagnostics, and rehabilitation services. The company was founded in 2014 and is headquartered in Tampere, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pihlajalinna Oyj reported revenue of €652M in FY2025 versus €578M in FY2021, a compound +3.1%/yr. Reported net income was €37.6M in FY2025, compounding +17.0%/yr from FY2021.
of which total revenue +11.4 pp · buybacks/dilution −3.5 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch PIHLIS: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Pihlajalinna Oyj with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pihlajalinna Oyj (PIHLIS) overvalued or undervalued?
What is the fair value of PIHLIS?
What is the quality score of PIHLIS?
What is the revenue of Pihlajalinna Oyj (PIHLIS)?
What is the net profit margin of PIHLIS?
Does Pihlajalinna Oyj pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pihlajalinna Oyj and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.